INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc & Encourages Investors wit...
November 15 2018 - 10:52PM
Business Wire
The Schall Law Firm, a national shareholder rights litigation
firm, announces that it is investigating claims on behalf of
investors of Alkermes plc (“Alkermes” or “the Company”) (NASDAQ:
ALKS) for violations of §§10(b) and 20(a) of the Securities
Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the
U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false
and/or misleading statements and/or failed to disclose information
pertinent to investors. The FDA issued a briefing document about
Alkermes’ new drug application for ALKS 5461 on October 30, 2018,
in advance of an FDA advisory committee meeting about the drug.
According to the briefing document, Alkermes “used an abridged
6-item version of the MADRS-10 for the primary endpoint of one of
the principal studies” instead of the “10-item diagnostic
questionnaire (MADRS-10)” despite the fact that the FDA provided
“advice explicitly against this plan.” The document also stated
that the FDA “disagreed with [Alkermes’] planned strategy to
average the MADRS results over several weeks, and recommended use
of the MADRS-10EOT, as used in other antidepressant studies and as
previously agreed.” Based on this news, Alkermes’ stock price fell
1.4% on the same day.
If you are a shareholder who suffered a loss, click here to
participate.
We also encourage you to contact Brian Schall, or Sherin
Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite
404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights
free of charge. You can also reach us through the firm's website
at www.schallfirm.com, or by email
at brian@schallfirm.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder
rights litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and rules of
ethics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181115006139/en/
The Schall Law FirmBrian Schall, Esq.Sherin Mahdavian,
Esq.310-301-3335info@schallfirm.comwww.schallfirm.com
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Sep 2023 to Sep 2024